BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 3408055)

  • 1. Histopathologic staging at initial diagnosis of mycosis fungoides and the Sézary syndrome. Definition of three distinctive prognostic groups.
    Sausville EA; Eddy JL; Makuch RW; Fischmann AB; Schechter GP; Matthews M; Glatstein E; Ihde DC; Kaye F; Veach SR
    Ann Intern Med; 1988 Sep; 109(5):372-82. PubMed ID: 3408055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic factors and evaluation of mycosis fungoides and Sézary syndrome.
    Toro JR; Stoll HL; Stomper PC; Oseroff AR
    J Am Acad Dermatol; 1997 Jul; 37(1):58-67. PubMed ID: 9216524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular staging of lymph nodes from 60 patients with mycosis fungoides and Sézary syndrome: correlation with histopathology and outcome suggests prognostic relevance in mycosis fungoides.
    Fraser-Andrews EA; Mitchell T; Ferreira S; Seed PT; Russell-Jones R; Calonje E; Whittaker SJ
    Br J Dermatol; 2006 Oct; 155(4):756-62. PubMed ID: 16965425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mycosis fungoides and the Sézary syndrome: pathology, staging, and treatment.
    Hoppe RT; Wood GS; Abel EA
    Curr Probl Cancer; 1990; 14(6):293-371. PubMed ID: 2245651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic factors, prognostic indices and staging in mycosis fungoides and Sézary syndrome: where are we now?
    Scarisbrick JJ; Kim YH; Whittaker SJ; Wood GS; Vermeer MH; Prince HM; Quaglino P
    Br J Dermatol; 2014 Jun; 170(6):1226-36. PubMed ID: 24641480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal.
    Agar NS; Wedgeworth E; Crichton S; Mitchell TJ; Cox M; Ferreira S; Robson A; Calonje E; Stefanato CM; Wain EM; Wilkins B; Fields PA; Dean A; Webb K; Scarisbrick J; Morris S; Whittaker SJ
    J Clin Oncol; 2010 Nov; 28(31):4730-9. PubMed ID: 20855822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic factors in erythrodermic mycosis fungoides and the Sézary syndrome.
    Kim YH; Bishop K; Varghese A; Hoppe RT
    Arch Dermatol; 1995 Sep; 131(9):1003-8. PubMed ID: 7661601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histologic assessment of lymph nodes in mycosis fungoides/Sézary syndrome (cutaneous T-cell lymphoma): clinical correlations and prognostic import of a new classification system.
    Sausville EA; Worsham GF; Matthews MJ; Makuch RW; Fischmann AB; Schechter GP; Gazdar AF; Bunn PA
    Hum Pathol; 1985 Nov; 16(11):1098-109. PubMed ID: 3876976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mycosis fungoides and Sézary syndrome: Current challenges in assessment, management and prognostic markers.
    Hughes CF; Newland K; McCormack C; Lade S; Prince HM
    Australas J Dermatol; 2016 Aug; 57(3):182-91. PubMed ID: 25988337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and Histological Characteristics of Mycosis Fungoides and Sézary Syndrome: A Retrospective, Single-centre Study of 43 Patients from Eastern Denmark.
    Nielsen PR; Eriksen JO; Wehkamp U; Lindahl LM; Gniadecki R; Fogh H; Fabricius S; Bzorek M; Ødum N; Gjerdrum LM
    Acta Derm Venereol; 2019 Dec; 99(13):1231-1236. PubMed ID: 31620804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic implications of a bone marrow histopathologic classification system in mycosis fungoides and the Sézary syndrome.
    Graham SJ; Sharpe RW; Steinberg SM; Cotelingam JD; Sausville EA; Foss FM
    Cancer; 1993 Aug; 72(3):726-34. PubMed ID: 8334625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advanced-stage mycosis fungoides and Sézary syndrome: survival and response to treatment.
    Alberti-Violetti S; Talpur R; Schlichte M; Sui D; Duvic M
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):e105-12. PubMed ID: 25817937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides and Sezary syndrome.
    Benton EC; Crichton S; Talpur R; Agar NS; Fields PA; Wedgeworth E; Mitchell TJ; Cox M; Ferreira S; Liu P; Robson A; Calonje E; Stefanato CM; Wilkins B; Scarisbrick J; Wain EM; Child F; Morris S; Duvic M; Whittaker SJ
    Eur J Cancer; 2013 Sep; 49(13):2859-68. PubMed ID: 23735705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic factor analysis in mycosis fungoides/Sézary syndrome.
    Diamandidou E; Colome M; Fayad L; Duvic M; Kurzrock R
    J Am Acad Dermatol; 1999 Jun; 40(6 Pt 1):914-24. PubMed ID: 10365922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression.
    Kim YH; Liu HL; Mraz-Gernhard S; Varghese A; Hoppe RT
    Arch Dermatol; 2003 Jul; 139(7):857-66. PubMed ID: 12873880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of T-cell receptor gene rearrangement in lymph nodes of patients with mycosis fungoides. Prognostic implications.
    Kern DE; Kidd PG; Moe R; Hanke D; Olerud JE
    Arch Dermatol; 1998 Feb; 134(2):158-64. PubMed ID: 9487207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of tumor burden in the blood of patients with erythrodermic primary cutaneous T-cell lymphoma.
    Scarisbrick JJ; Whittaker S; Evans AV; Fraser-Andrews EA; Child FJ; Dean A; Russell-Jones R
    Blood; 2001 Feb; 97(3):624-30. PubMed ID: 11157477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model.
    Scarisbrick JJ; Prince HM; Vermeer MH; Quaglino P; Horwitz S; Porcu P; Stadler R; Wood GS; Beylot-Barry M; Pham-Ledard A; Foss F; Girardi M; Bagot M; Michel L; Battistella M; Guitart J; Kuzel TM; Martinez-Escala ME; Estrach T; Papadavid E; Antoniou C; Rigopoulos D; Nikolaou V; Sugaya M; Miyagaki T; Gniadecki R; Sanches JA; Cury-Martins J; Miyashiro D; Servitje O; Muniesa C; Berti E; Onida F; Corti L; Hodak E; Amitay-Laish I; Ortiz-Romero PL; Rodríguez-Peralto JL; Knobler R; Porkert S; Bauer W; Pimpinelli N; Grandi V; Cowan R; Rook A; Kim E; Pileri A; Patrizi A; Pujol RM; Wong H; Tyler K; Stranzenbach R; Querfeld C; Fava P; Maule M; Willemze R; Evison F; Morris S; Twigger R; Talpur R; Kim J; Ognibene G; Li S; Tavallaee M; Hoppe RT; Duvic M; Whittaker SJ; Kim YH
    J Clin Oncol; 2015 Nov; 33(32):3766-73. PubMed ID: 26438120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mycosis Fungoides and Sezary Syndrome.
    Foss FM; Girardi M
    Hematol Oncol Clin North Am; 2017 Apr; 31(2):297-315. PubMed ID: 28340880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical characteristics, prognostic factors, and survival of 393 patients with mycosis fungoides and Sézary syndrome in the southeastern United States: a single-institution cohort.
    Desai M; Liu S; Parker S
    J Am Acad Dermatol; 2015 Feb; 72(2):276-85. PubMed ID: 25458019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.